QPS will exhibit at the World Vaccine Congress, April 15-17 in Washington, DC. Please stop by our booth #600 to learn more about QPS’ capabilities in vaccine trials. Find out more at Vaccines or email: infobd@www.qps.com
QPS will exhibit at the World Vaccine Congress Read More »
Later this month the United Kingdom (UK) is expected to achieve independence from the European Union (EU) based on a referendum that was passed in June 2016. Yet Britain’s exit, or “Brexit,” leaves us with more questions than answers right now. We have been watching and waiting, with clarity expected on March 29, 2019, the
BREXIT IMPACT: More Questions Than Answers Read More »
QPS is exhibiting at the 13th Annual WRIB Meeting, April 1-4 in New Orleans, LA. If you are attending, please visit us at booth #49. Contact us at info@qps.com for additional information.
QPS is exhibiting at the 13th Annual WRIB Meeting Read More »
QPS will exhibit at the 4th Annual Neuroscience R&D Technologies Conference, October 4-5 in Munich, Germany. Please stop by our Booth #5 to learn more about QPS’ contract research services. Find out more at qpsneuro.com or email office-austria@www.qps.com #NeuroRnD #QPSLLC #CRO
QPS will exhibit at the 14th International Conference on Alzheimer’s & Parkinson’s Disease, March 26-31 in Lisbon, Portugal. Please stop by our booth #28 to learn more about QPS’ contract research services. Find out more at qpsneuro.com or email office-austria@www.qps.com
QPS is exhibiting at the 3rd Annual Gene Therapy for Rare Disorders Conference, between March 26-28 in Boston, MA. If you are attending the meeting, please visit us to learn more about QPS’ range of services. We have supported gene therapy since 2002: ASOs, siRNAs, miRNA through mRNAs and viral vectors utilizing LC-HRMS, hybridization-LC, and
QPS is exhibiting at the 3rd Annual Gene Therapy for Rare Disorders Conference Read More »
Shoulder to shoulder with our clients, we at QPS like to share the results of our early clinical research efforts, published in the scientific literature. Learn more by reading: A Phase 1, Single-center, Double-blind, Placebo-controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Clinical Effects, and Pharmacokinetics-Pharmacodynamics of Intravenous Cyclopropyl-methoxycarbonylmetomidate (ABP-700) after a Single
Spreading Early Clinical Knowledge Read More »
Goodbye boutique CRO, hello large study BIG PLAYER! For a long time, you’ve known us as THE high quality outfit that can stabilize difficult assays in the initial stages of clinical investigation. But we’ve been investing in additional technical personnel and laboratory capacity for translational medicine at our Flagship Delaware Technology Park facility. And now
Translational Medicine Now Bigger and Better at QPS Read More »
The 2017 Transdermal & Intradermal Drug Delivery Systems conference covering Advanced Design, Development & Delivery of Skin-Mediated Therapies and Vaccines is coming up on September 28-29 at the venerable Racquet Club of Philadelphia. Don’t miss Paul Lehman, VP and Head of Dermal & Transdermal Research Services at QPS, presenting “Evolution of the In Vitro Permeation
QPS’ Paul Lehman to Speak at Transdermal & Intradermal Drug Delivery Conference Read More »
Two companies have just selected QPS Netherlands to conduct their First-in-Human studies. Acticor Biotech, a Paris-based biotechnology company focused on the treatment of acute ischemic stroke, selected the QPS facility in Groningen, The Netherlands, to manage a Phase I clinical study. The goal of the study is to assess safety and tolerance as well as
QPS Tapped for Two New FIH Studies Read More »
An investigation into the efficacy and safety of Estetrol (E4) for potential use in the treatment of advanced prostate cancer demonstrated decreased testosterone levels along with acceptable safety parameters. These results suggest that E4 may be suitable for standalone or combination treatment with androgen deprivation therapy (ADT). QPS Netherlands performed the Phase II randomized, double-blind,
QPS Study Shows Estetrol Promising for Prostate Cancer Treatment Read More »
QPS is the main sponsor of the Analytical and Bioanalytical Day at the 7th World ADC Meeting, February 20 – 22, 2017 at the Maritim proArte Hotel in Berlin this week. Over 300 enthusiasts are expected to attend. Our Director of Biologics/Mass Spectrometry, Dr. Fabrizia Fusetti, gave a presentation on a multidisciplinary approach for bioanalysis
QPS Sponsors Day 1 of World ADC Meeting in Berlin Read More »
For all you assay aficionados out there, we thought you’d be juiced to know — we just added a whopping 47 new assays to the QPS Assay Finder Database: Agomelatine; Albendazole + metabolite; Amphetamine; Apixaban; Apremilast; Atazanavir; Atorvastatin + metabolites; Bosutinib; Bupropion + metabolites; Caffeine + metabolites; Carbamazepine + metabolite; Cetirizine; Chlorzoxazone; Colchicine; Dexamethasone; Dolutegravir;
QPS Assay Finder Database Grows 47 New Assays! Read More »
At QPS, we love making customers happy. Here’s what two of them had to say about our work in DMPK protein binding studies: First of all, my compliments and thanks for the work that Wenbin and the other members of the QPS team did on the XYZ protein binding study. Lots of samples, lots of
Client Feedback — Our Gold Standard Read More »
For outstanding performance including growth in sales, continuous growth in minority business to minority business purchases, innovation in the delivery of services, significant and continuous contribution to the growth and development of our community, and commitment to the cause and success of the EMSDC, QPS has been named Class IV Supplier of the Year! The
Mr. Sanjay Mitter joined QPS as VP and Global Head of Clinical Research Services. He is currently responsible for Clinical Research, i.e. global pharmacokinetics, data management, biostatistics, medical writing and publishing. He also oversees clinical monitoring and project management in the US. Sanjay comes to us fresh from a stint as Global Director of Biostatistics,
Sanjay Mitter new VP and Global Head of Clinical Research Services Read More »
Join us from July 24-27, 2016 in Toronto, Canada for the Alzheimer’s Association International Conference. QPS neuroscientists will attend the AAIC 2016 and would be pleased to meet you there at our booth#207 to discuss potential and ongoing projects. QPS posters presented: Sunday, July 24, 2016, 9:30 AM to 10:30 AM (Session: P1-02-062, Poster: #12005)
Let’s Talk Neuro at the AAIC 2016 in Toronto, Canada, July 24-27, 2016 Read More »
Since 2012, a New Investigator Award has been given annually to honor excellence among bioanalytical scientists within their first five years in the industry. In this regard, Daniel Wilffert, a 2016 award nominee from QPS Netherlands, is truly fresh off the starting blocks. He started @QPS Holdings LLC last August and only just defended his
We are exhibiting at the DIA 2016 Annual Meeting at our booth #1200 between June 26-30 at Philadelphia, PA, USA. If you are attending the meeting, please stop by to learn more about QPS’ Early Phase Clinical and Bioanalytical Services, including: Reputation for Flexibility and Responsiveness Global Reach: 500+ Clinical beds (6 Worldwide Clinics) 20+
QPS CEO Ben Chien has made it through to the round of 30 (31, actually) being considered for this year’s prestigious EY Entrepreneur Of The Year Award for the Greater Philadelphia area. The only competitive awards program in the world for entrepreneurs and leaders of high-growth companies, the 30 year-old program operates in 145 cities
Ben Chien is an EY Entrepreneur Of The Year® 2016 Finalist for Greater Philadelphia! Read More »
Delaware Technology Park,
3 Innovation Way,
Newark, DE 19711
"*" indicates required fields
